Update on Menopausal Hormone Therapy for Fracture Prevention

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F19%3AN0000083" target="_blank" >RIV/00023728:_____/19:N0000083 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10409678 RIV/00064165:_____/19:10409678
Result on the web
<a href="https://doi.org/10.1007/s11914-019-00549-3" target="_blank" >https://doi.org/10.1007/s11914-019-00549-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11914-019-00549-3" target="_blank" >10.1007/s11914-019-00549-3</a>

Result language
angličtina
Original language name
Update on Menopausal Hormone Therapy for Fracture Prevention
Original language description
The goal of the review is to assess the appropriateness of menopausal hormone therapy (MHT) for the primary prevention of bone loss in women at elevated risk in the early years after menopause. Estrogen alone or combined with progestin to protect the uterus from cancer significantly reduces the risk of osteoporosis-related fractures. MHT increases type 1 collagen production and osteoblast survival and maintains the equilibrium between bone resorption and bone formation by modulating osteoblast/osteocyte and T cell regulation of osteoclasts. Estrogens have positive effects on muscle and cartilage. Estrogen, but not antiresorptive therapies, can attenuate the inflammatory bone-microenvironment associated with estrogen deficiency. However, already on second year of administration, MHT is associated with excess breast cancer risk, increasing steadily with duration of use. MHT should be considered in women with premature estrogen deficiency and increased risk of bone loss and osteoporotic fractures. However, MHT use for the prevention of bone loss is hindered by increase in breast cancer risk even in women younger than 60 years old or who are within 10 years of menopause onset.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30226 - Rheumatology

Project
<a href="/en/project/NV18-05-00394" target="_blank" >NV18-05-00394: Study on association between intestinal microbiome and increased risk of chronic inflammatory diseases of locomotor system, osteoporosis and rheumatoid arthritis.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)